Danaher to Divest Assets to Satisfy FTC Conditions on GE Biopharma Acquisition
March 19 2020 - 6:56PM
Dow Jones News
By Stephen Nakrosis
The U.S. Federal Trade Commission on Thursday said Danaher Corp.
has agreed to divest some assets as a condition to its proposed
acquisition of GE Biopharma.
The FTC said the $21.4 billion deal would violate U.S. antitrust
laws by lessening competition "in highly concentrated product
markets for 10 products that companies use to manufacture
biopharmaceutical drugs."
Under the terms of the deal, the FTC said, Danaher will "divest
all rights and assets to research, develop, manufacture, market,
and sell these products" to Germany's Sartorius AG.
In February of last year, General Electric Co. said it would
sell the GE Biopharma business to Danaher.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 19, 2020 18:41 ET (22:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Danaher (NYSE:DHR)
Historical Stock Chart
From Sep 2023 to Sep 2024